Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 4
2010 6
2011 7
2012 16
2013 24
2014 29
2015 23
2016 20
2017 23
2018 25
2019 39
2020 55
2021 46
2022 43
2023 49
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

390 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bpdc (239 results)?
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ, Wilson NR, Pemmaraju N. Adimora IJ, et al. Cancer. 2022 Aug 15;128(16):3019-3026. doi: 10.1002/cncr.34345. Epub 2022 Jun 21. Cancer. 2022. PMID: 35726525 Free article. Review.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from precursor dendritic cells. BPDCN cells characteristically express several markers on their cell surfaces including CD123, CD4, and CD56. ...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from precursor dendritic cells. BPDC
Targeting CD123 in BPDCN: an emerging field.
DiPippo AJ, Wilson NR, Pemmaraju N. DiPippo AJ, et al. Expert Rev Hematol. 2021 Nov;14(11):993-1004. doi: 10.1080/17474086.2021.1988848. Epub 2021 Oct 29. Expert Rev Hematol. 2021. PMID: 34607517 Review.
AREAS COVERED: CD123 (also known as IL-3 Ralpha) is a cell surface marker and attractive therapeutic target for many myeloid malignancies, particularly BPDCN, whose cells ubiquitously overexpress CD123. We review the history of CD123 research regarding BPDCN, recent …
AREAS COVERED: CD123 (also known as IL-3 Ralpha) is a cell surface marker and attractive therapeutic target for many myeloid malignancies, p …
Conventional Therapeutics in BPDCN Patients-Do They Still Have a Place in the Era of Targeted Therapies?
Poussard M, Angelot-Delettre F, Deconinck E. Poussard M, et al. Cancers (Basel). 2022 Aug 2;14(15):3767. doi: 10.3390/cancers14153767. Cancers (Basel). 2022. PMID: 35954431 Free PMC article. Review.
No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the malignancy is chemo-sensitive, chemotherapy followed by hematopoietic stem cell transplantation remains an effective treatment. ...In this review, we focus on conventional the …
No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the malignancy is chemo-sensitive, chem …
Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.
Cazzato G, Capuzzolo M, Bellitti E, De Biasi G, Colagrande A, Mangialardi K, Gaudio F, Ingravallo G. Cazzato G, et al. Hematol Rep. 2023 Dec 8;15(4):696-706. doi: 10.3390/hematolrep15040070. Hematol Rep. 2023. PMID: 38132278 Free PMC article. Review.
In August-September 2023, we searched MEDLINE, PubMed and Scopus for randomized controlled trials (RCTs), narrative and systematic reviews, meta-analyses, observational studies (either longitudinal or retrospective), and case series published in English in the last 25 years using …
In August-September 2023, we searched MEDLINE, PubMed and Scopus for randomized controlled trials (RCTs), narrative and systematic reviews, …
Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A, Sweet K. Jain A, et al. J Natl Compr Canc Netw. 2023 May;21(5):515-521. doi: 10.6004/jnccn.2023.7026. J Natl Compr Canc Netw. 2023. PMID: 37156483 Review.
BPDCN is most often characterized by its presentation with distinct cutaneous lesions. ...Expression of CD4, CD56, and CD123 is the hallmark of BPDCN. The presence of 4 of CD4, CD56, CD123, TCL1, TCF4, and CD303 is necessary for the diagnosis of BPDCN. ...
BPDCN is most often characterized by its presentation with distinct cutaneous lesions. ...Expression of CD4, CD56, and CD123 is the h
Plasmacytoid dendritic cell neoplasms.
Lee YJ, Kim Y, Park SH, Jo JC. Lee YJ, et al. Blood Res. 2023 Apr 30;58(S1):90-95. doi: 10.5045/br.2023.2023052. Blood Res. 2023. PMID: 37105563 Free PMC article. Review.
In contrast, BPDCN is a clinically aggressive myeloid malignancy involving the skin, bone marrow, lymphatic organs, and central nervous system. ...The expression of CD4, CD56, CD123, and pDC markers (TCL-1, TCF4, CD303, and CD304, etc.) are typical immunophenotype of BP
In contrast, BPDCN is a clinically aggressive myeloid malignancy involving the skin, bone marrow, lymphatic organs, and central nervo …
Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Alfayez M, Konopleva M, Pemmaraju N. Alfayez M, et al. Expert Opin Biol Ther. 2020 Feb;20(2):115-123. doi: 10.1080/14712598.2020.1701651. Epub 2019 Dec 17. Expert Opin Biol Ther. 2020. PMID: 31801379 Review.
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has historically been limited by small numbers of patients in the target population. In recent years, the development of tagraxofusp (SL-401) (ELZONR …
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has histo …
Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP, Rizzieri D, Pemmaraju N. Economides MP, et al. Curr Hematol Malig Rep. 2019 Dec;14(6):515-522. doi: 10.1007/s11899-019-00556-2. Curr Hematol Malig Rep. 2019. PMID: 31853773 Review.
PURPOSE OF REVIEW: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that has heterogeneous presentation and can involve the skin, lymph nodes, and bone marrow. Recent advancements in our patho-biologic understandi …
PURPOSE OF REVIEW: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that …
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR, Konopleva M, Khoury JD, Pemmaraju N. Wilson NR, et al. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):734-740. doi: 10.1016/j.clml.2021.05.018. Epub 2021 Jun 10. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34226167 Review.
Characteristically unique from other myeloid neoplasms, BPDCN cells express CD4, CD56, and CD123 as well as TCL-1 and TCF4 in almost all cases. ...Specifically, the use of venetoclax in targeting BCL2 has been promising in BPDCN treatment. This review will focus on …
Characteristically unique from other myeloid neoplasms, BPDCN cells express CD4, CD56, and CD123 as well as TCL-1 and TCF4 in almost …
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, Wang ES, Foran J, Lane AA. Pemmaraju N, et al. Leuk Lymphoma. 2024 May;65(5):548-559. doi: 10.1080/10428194.2024.2305288. Epub 2024 Feb 23. Leuk Lymphoma. 2024. PMID: 38391126 Review.
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and is characterized by CD123 overexpression, which is seen in all patients with BPDCN. The CD123-directed therapy tagraxofusp is the only
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and i
390 results